Literature DB >> 9778257

Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis.

R Paul1, S Lorenzl, U Koedel, B Sporer, U Vogel, M Frosch, H W Pfister.   

Abstract

In this study, we investigated the involvement of matrix metalloproteinases (MMPs) in the pathophysiology of bacterial meningitis. By using an enzyme immunoassay, high concentrations of MMP-9 were detected in the cerebrospinal fluid (CSF) of adult patients with bacterial meningitis but not in controls, and in patients with Guillain-Barré syndrome. Moreover, we observed significantly elevated concentrations of the tissue inhibitor of metalloproteinase-1 (TIMP-1) in the CSF of patients with bacterial meningitis, compared with controls. In a rat model of meningococcal meningitis, intracisternal injection of heat-killed meningococci caused a disruption of the blood-brain barrier (BBB), an increase in intracranial pressure, and CSF pleocytosis paralleled by the occurrence of MMP-9 activity in the CSF 6 hours after meningococcal challenge. The MMP inhibitor batimastat (BB-94) significantly reduced the BBB disruption and the increase in intracranial pressure irrespective of the time of batimastat administration (15 minutes before and 3 hours after meningococcal challenge) but failed to significantly reduce CSF white blood cell counts. In conclusion, our results suggest that MMPs are involved in the alterations of BBB permeability during experimental meningococcal meningitis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9778257     DOI: 10.1002/ana.410440404

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  45 in total

1.  New Advances in the Pathogenesis and Pathophysiology of Bacterial Meningitis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

Review 2.  Reprogramming the host response in bacterial meningitis: how best to improve outcome?

Authors:  M van der Flier; S P M Geelen; J L L Kimpen; I M Hoepelman; E I Tuomanen
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

3.  Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis.

Authors:  S L Leib; D Leppert; J Clements; M G Täuber
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 4.  Management of intracranial pressure in tuberculous meningitis.

Authors:  J M K Murthy
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 5.  Development of adjunctive therapies for bacterial meningitis and lessons from knockout mice.

Authors:  Robert Paul; Uwe Koedel; Hans-Walter Pfister
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

6.  Persisting vasculitis after pneumococcal meningitis.

Authors:  Deborah Pugin; Jean-Christophe Copin; Marie-Christelle Goodyear; Theodor Landis; Yvan Gasche
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 7.  The paradox of matrix metalloproteinases in infectious disease.

Authors:  P T G Elkington; C M O'Kane; J S Friedland
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

8.  Association of plasminogen activators and matrix metalloproteinase-9 proteolytic cascade with blood-CNS barrier damage of angiostrongyliasis.

Authors:  Ke-Min Chen; Jer-Yuh Liu; Shih-Chan Lai; Li-Sung Hsu; Hsiu-Hsiung Lee
Journal:  Int J Exp Pathol       Date:  2006-04       Impact factor: 1.925

9.  Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis.

Authors:  Damian N Meli; Roney S Coimbra; Dominik G Erhart; Gerard Loquet; Caroline L Bellac; Martin G Täuber; Ulf Neumann; Stephen L Leib
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

10.  Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.

Authors:  Stefan Lorenzl; Noel Calingasan; Lichuan Yang; David S Albers; Shuei Shugama; Jason Gregorio; H W Krell; Jason Chirichigno; Tong Joh; M Flint Beal
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.